Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Of Infigratinib For The Adjuvant Treatment Of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302) Read more
A Study Of Enfortumab Vedotin (ASG-22CE) As Monotherapy Or In Combination With Other Anticancer Therapies For The Treatment Of Urothelial Cancer Read more
Phase III Randomized Trial Of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery Or Radiation) Of The Primary Tumor In Metastatic Prostate Cancer Read more
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With Or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer Read more
Intuitive Surgical, Protocol: ISI-IRIS-002 , PI: Dr. Stifelman, Title: A Prospective Post-Market Study To Evaluate The Clinical Utility Of IRISTM, A Three-Dimensional (3-D) Anatomical Modeling Software For Pre-Operative Surgical Planning And Intra-Operative Navigation For Nephrectomy Read more
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study Of Nivolumabversus Placebo In Combination With Neoadjuvant Chemotherapy And Adjuvant Endocrine Therapy In Patients With High-Risk, Estrogen Receptor-Positive (ER+), Human Epidermalgrowth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer Read more
